OR WAIT null SECS
SEATTLE, WA, January 15, 2008-Dendreon Corporation today announced that the company has been granted a broad European patent covering the company’s lead product candidate Provenge® (sipuleucel-T), the company’s investigational active cellular immunotherapy for the treatment of advanced prostate cancer. European patent No. 0 870 022 B1 covers the composition of matter of Provenge as well as the company’s other active cellular immunotherapy (ACI) product candidates, such as Neuvenge™ (lapuleucel-T), which utilize Dendreon’s Antigen Delivery Cassette™ technology. The patent also covers methods of activating antigen presenting cells in vitro with certain fusion proteins developed by Dendreon, including the fusion protein that is used in Provenge.